Monotherapy with Roche's Hivid
Executive Summary
During the week of Aug. 8, FDA is expected to approve monotherapy use of Hivid (ddC) in HIV infection. Although currently approved only for use with AZT in advanced HIV, Hivid is already widely prescribed as monotherapy. In September 1993, FDA's Antiviral Drugs Advisory Committee recommended that ddC be approved as second-line monotherapy for adults with advanced HIV who have shown intolerance to AZT or significant clinical deterioration with AZT